{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T07:14:32Z","timestamp":1792134872094,"version":"4.4.0"},"reference-count":82,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T00:00:00Z","timestamp":1718841600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T00:00:00Z","timestamp":1718841600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Klinikum der Universit\u00e4t M\u00fcnchen"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2024,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>To provide practice guideline\/procedure standards for diagnostics and therapy (theranostics) of meningiomas using radiolabeled somatostatin receptor (SSTR) ligands.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This joint practice guideline\/procedure standard was collaboratively developed by the European Association of Nuclear Medicine (EANM), the Society of Nuclear Medicine and Molecular Imaging (SNMMI), the European Association of Neurooncology (EANO), and the PET task force of the Response Assessment in Neurooncology Working Group (PET\/RANO).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Positron emission tomography (PET) using somatostatin receptor (SSTR) ligands can detect meningioma tissue with high sensitivity and specificity and may provide clinically relevant information beyond that obtained from structural magnetic resonance imaging (MRI) or computed tomography (CT) imaging alone. SSTR-directed PET imaging can be particularly useful for differential diagnosis, delineation of meningioma extent, detection of osseous involvement, and the differentiation between posttherapeutic scar tissue and tumour recurrence. Moreover, SSTR-peptide receptor radionuclide therapy (PRRT) is an emerging investigational treatment approach for meningioma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>These practice guidelines will define procedure standards for the application of PET imaging in patients with meningiomas and related SSTR-targeted PRRTs in routine practice and clinical trials and will help to harmonize data acquisition and interpretation across centers, facilitate comparability of studies, and to collect larger databases. The current document provides additional information to the evidence-based recommendations from the PET\/RANO Working Group regarding the utilization of PET imaging in meningiomas Galldiks (Neuro Oncol. 2017;19(12):1576\u201387). The information provided should be considered in the context of local conditions and regulations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00259-024-06783-x","type":"journal-article","created":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T22:01:26Z","timestamp":1718834486000},"page":"3662-3679","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":82,"title":["Joint EANM\/EANO\/RANO\/SNMMI practice guideline\/procedure standards for diagnostics and therapy (theranostics) of meningiomas using radiolabeled somatostatin receptor ligands: version 1.0"],"prefix":"10.1007","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0953-7624","authenticated-orcid":false,"given":"Nathalie L.","family":"Albert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3541-2315","authenticated-orcid":false,"given":"Matthias","family":"Preusser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1118-926X","authenticated-orcid":false,"given":"Tatjana","family":"Traub-Weidinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8005-2833","authenticated-orcid":false,"given":"Nelleke","family":"Tolboom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Law","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3311-0129","authenticated-orcid":false,"given":"Joshua D.","family":"Palmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Guedj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8258-3681","authenticated-orcid":false,"given":"Julia","family":"Furtner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Fraioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond Y.","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek R.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6080-1577","authenticated-orcid":false,"given":"Christophe M.","family":"Deroose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9662-7259","authenticated-orcid":false,"given":"Ken","family":"Herrmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Vogelbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joerg-Christian","family":"Tonn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Weller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick Y.","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin J.","family":"van den Bent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Verger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jana","family":"Ivanidze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norbert","family":"Galldiks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,20]]},"reference":[{"key":"6783_CR1","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1002\/(sici)1097-0215(19980529)76:5<620::aid-ijc2>3.0.co;2-s","volume":"76","author":"A Dutour","year":"1998","unstructured":"Dutour A, Kumar U, Panetta R, Ouafik L, Fina F, Sasi R, et al. Expression of somatostatin receptor subtypes in human brain tumors. Int J Cancer. 1998;76:620\u20137. https:\/\/doi.org\/10.1002\/(sici)1097-0215(19980529)76:5%3c620::aid-ijc2%3e3.0.co;2-s.","journal-title":"Int J Cancer"},{"key":"6783_CR2","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s41181-022-00176-x","volume":"7","author":"C Wangler","year":"2022","unstructured":"Wangler C, Beyer L, Bartenstein P, Wangler B, Schirrmacher R, Lindner S. Favorable SSTR subtype selectivity of SiTATE: new momentum for clinical [(18)F]SiTATE PET. EJNMMI Radiopharm Chem. 2022;7:22. https:\/\/doi.org\/10.1186\/s41181-022-00176-x.","journal-title":"EJNMMI Radiopharm Chem"},{"key":"6783_CR3","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1007\/s11060-013-1146-y","volume":"113","author":"S Wang","year":"2013","unstructured":"Wang S, Yang W, Deng J, Zhang J, Ma F, Wang J. Correlation between 99mTc-HYNIC-octreotide SPECT\/CT somatostatin receptor scintigraphy and pathological grading of meningioma. J Neurooncol. 2013;113:519\u201326. https:\/\/doi.org\/10.1007\/s11060-013-1146-y.","journal-title":"J Neurooncol"},{"key":"6783_CR4","doi-asserted-by":"publisher","first-page":"937","DOI":"10.2967\/jnumed.118.230607","volume":"60","author":"TA Hope","year":"2019","unstructured":"Hope TA, Abbott A, Colucci K, Bushnell DL, Gardner L, Graham WS, et al. NANETS\/SNMMI Procedure Standard for Somatostatin Receptor-Based Peptide Receptor Radionuclide Therapy with (177)Lu-DOTATATE. J Nucl Med. 2019;60:937\u201343. https:\/\/doi.org\/10.2967\/jnumed.118.230607.","journal-title":"J Nucl Med"},{"key":"6783_CR5","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1093\/neuonc\/nou131","volume":"17","author":"A Afshar-Oromieh","year":"2015","unstructured":"Afshar-Oromieh A, Wolf MB, Kratochwil C, Giesel FL, Combs SE, Dimitrakopoulou-Strauss A, et al. Comparison of (6)(8)Ga-DOTATOC-PET\/CT and PET\/MRI hybrid systems in patients with cranial meningioma: Initial results. Neuro Oncol. 2015;17:312\u20139. https:\/\/doi.org\/10.1093\/neuonc\/nou131.","journal-title":"Neuro Oncol"},{"key":"6783_CR6","doi-asserted-by":"publisher","first-page":"347","DOI":"10.2967\/jnumed.114.149120","volume":"56","author":"W Rachinger","year":"2015","unstructured":"Rachinger W, Stoecklein VM, Terpolilli NA, Haug AR, Ertl L, Poschl J, et al. Increased 68Ga-DOTATATE uptake in PET imaging discriminates meningioma and tumor-free tissue. J Nucl Med. 2015;56:347\u201353. https:\/\/doi.org\/10.2967\/jnumed.114.149120.","journal-title":"J Nucl Med"},{"key":"6783_CR7","doi-asserted-by":"publisher","unstructured":"Graef J, Furth C, Kluge AK, Acker G, Kord M, Zimmermann Z, et al. 68Ga-DOTATOC-PET\/MRI-A Secure One-Stop Shop Imaging Tool for Robotic Radiosurgery Treatment Planning in Patients with Optic Nerve Sheath Meningioma. Cancers (Basel). 2021;13. https:\/\/doi.org\/10.3390\/cancers13133305.","DOI":"10.3390\/cancers13133305"},{"key":"6783_CR8","doi-asserted-by":"publisher","first-page":"9064","DOI":"10.1038\/s41598-021-87866-9","volume":"11","author":"HC Einhellig","year":"2021","unstructured":"Einhellig HC, Siebert E, Bauknecht HC, Tietze A, Graef J, Furth C, et al. Comparison of diagnostic value of 68 Ga-DOTATOC PET\/MRI and standalone MRI for the detection of intracranial meningiomas. Sci Rep. 2021;11:9064. https:\/\/doi.org\/10.1038\/s41598-021-87866-9.","journal-title":"Sci Rep"},{"key":"6783_CR9","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-023-06315-z","author":"M Unterrainer","year":"2023","unstructured":"Unterrainer M, Kunte SC, Unterrainer LM, Holzgreve A, Delker A, Lindner S, et al. Next-generation PET\/CT imaging in meningioma-first clinical experiences using the novel SSTR-targeting peptide [(18)F]SiTATE. Eur J Nucl Med Mol Imaging. 2023. https:\/\/doi.org\/10.1007\/s00259-023-06315-z.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6783_CR10","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.2967\/jnumed.117.191932","volume":"58","author":"WG Kunz","year":"2017","unstructured":"Kunz WG, Jungblut LM, Kazmierczak PM, Vettermann FJ, Bollenbacher A, Tonn JC, et al. Improved detection of transosseous meningiomas using (68)Ga-DOTATATE PET\/CT compared with contrast-enhanced MRI. J Nucl Med. 2017;58:1580\u20137. https:\/\/doi.org\/10.2967\/jnumed.117.191932.","journal-title":"J Nucl Med"},{"key":"6783_CR11","doi-asserted-by":"publisher","first-page":"vdab012","DOI":"10.1093\/noajnl\/vdab012","volume":"3","author":"SS Mahase","year":"2021","unstructured":"Mahase SS, Roth O\u2019Brien DA, No D, Roytman M, Skafida ME, Lin E, et al. [(68)Ga]-DOTATATE PET\/MRI as an adjunct imaging modality for radiation treatment planning of meningiomas. Neurooncol Adv. 2021;3:vdab012. https:\/\/doi.org\/10.1093\/noajnl\/vdab012.","journal-title":"Neurooncol Adv."},{"key":"6783_CR12","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.ijrobp.2005.12.006","volume":"65","author":"S Milker-Zabel","year":"2006","unstructured":"Milker-Zabel S, Zabel-du Bois A, Henze M, Huber P, Schulz-Ertner D, Hoess A, et al. Improved target volume definition for fractionated stereotactic radiotherapy in patients with intracranial meningiomas by correlation of CT, MRI, and [68Ga]-DOTATOC-PET. Int J Radiat Oncol Biol Phys. 2006;65:222\u20137. https:\/\/doi.org\/10.1016\/j.ijrobp.2005.12.006.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"6783_CR13","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/j.ijrobp.2022.04.009","volume":"113","author":"HK Perlow","year":"2022","unstructured":"Perlow HK, Siedow M, Gokun Y, McElroy J, Matsui J, Zoller W, et al. (68)Ga-DOTATATE PET-Based Radiation Contouring Creates More Precise Radiation Volumes for Patients With Meningioma. Int J Radiat Oncol Biol Phys. 2022;113:859\u201365. https:\/\/doi.org\/10.1016\/j.ijrobp.2022.04.009.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"6783_CR14","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJMoa1607427","volume":"376","author":"J Strosberg","year":"2017","unstructured":"Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, et al. Phase 3 Trial of (177)Lu-Dotatate for Midgut Neuroendocrine Tumors. N Engl J Med. 2017;376:125\u201335. https:\/\/doi.org\/10.1056\/NEJMoa1607427.","journal-title":"N Engl J Med"},{"key":"6783_CR15","doi-asserted-by":"publisher","first-page":"507","DOI":"10.2967\/jnumed.120.249607","volume":"62","author":"C Mirian","year":"2021","unstructured":"Mirian C, Duun-Henriksen AK, Maier A, Pedersen MM, Jensen LR, Bashir A, et al. Somatostatin receptor-targeted radiopeptide therapy in treatment-refractory Meningioma: Individual patient data meta-analysis. J Nucl Med. 2021;62:507\u201313. https:\/\/doi.org\/10.2967\/jnumed.120.249607.","journal-title":"J Nucl Med"},{"key":"6783_CR16","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1007\/s00259-018-4207-9","volume":"46","author":"I Law","year":"2019","unstructured":"Law I, Albert NL, Arbizu J, Boellaard R, Drzezga A, Galldiks N, et al. Joint EANM\/EANO\/RANO practice guidelines\/SNMMI procedure standards for imaging of gliomas using PET with radiolabelled amino acids and [(18)F]FDG: version 1.0. Eur J Nucl Med Mol Imaging. 2019;46:540\u201357. https:\/\/doi.org\/10.1007\/s00259-018-4207-9.","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"6783_CR17","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1007\/s00259-012-2330-6","volume":"40","author":"JJ Zaknun","year":"2013","unstructured":"Zaknun JJ, Bodei L, Mueller-Brand J, Baum RP, Pavel ME, Horsch D, et al. The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2013;40:800\u201316. https:\/\/doi.org\/10.1007\/s00259-012-2330-6.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6783_CR18","doi-asserted-by":"publisher","first-page":"222","DOI":"10.2967\/jnumed.119.240911","volume":"61","author":"TA Hope","year":"2020","unstructured":"Hope TA, Bodei L, Chan JA, El-Haddad G, Fidelman N, Kunz PL, et al. NANETS\/SNMMI Consensus Statement on Patient Selection and Appropriate Use of (177)Lu-DOTATATE Peptide Receptor Radionuclide Therapy. J Nucl Med. 2020;61:222\u20137. https:\/\/doi.org\/10.2967\/jnumed.119.240911.","journal-title":"J Nucl Med"},{"key":"6783_CR19","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3109\/01676830.2014.959185","volume":"34","author":"A Klingenstein","year":"2015","unstructured":"Klingenstein A, Haug AR, Miller C, Hintschich C. Ga-68-DOTA-TATE PET\/CT for discrimination of tumors of the optic pathway. Orbit. 2015;34:16\u201322. https:\/\/doi.org\/10.3109\/01676830.2014.959185.","journal-title":"Orbit"},{"key":"6783_CR20","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1007\/s00259-012-2155-3","volume":"39","author":"A Afshar-Oromieh","year":"2012","unstructured":"Afshar-Oromieh A, Giesel FL, Linhart HG, Haberkorn U, Haufe S, Combs SE, et al. Detection of cranial meningiomas: comparison of (6)(8)Ga-DOTATOC PET\/CT and contrast-enhanced MRI. Eur J Nucl Med Mol Imaging. 2012;39:1409\u201315. https:\/\/doi.org\/10.1007\/s00259-012-2155-3.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6783_CR21","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1097\/RLU.0000000000002513","volume":"44","author":"M Unterrainer","year":"2019","unstructured":"Unterrainer M, Ruf V, Ilhan H, Vettermann FJ, Cyran CC, Niyazi M, et al. 68Ga-DOTATOC PET\/CT Differentiates Meningioma From Dural Metastases. Clin Nucl Med. 2019;44:412\u20133. https:\/\/doi.org\/10.1097\/RLU.0000000000002513.","journal-title":"Clin Nucl Med"},{"key":"6783_CR22","doi-asserted-by":"publisher","unstructured":"Kunz WG, Jungblut LM, Kazmierczak PM, Vettermann FJ, Bollenbacher A, Tonn JC, et al. Improved Detection of Transosseous Meningiomas Using 68Ga-DOTATATE PET-CT Compared to Contrast-Enhanced MRI. J Nucl Med. 2017. https:\/\/doi.org\/10.2967\/jnumed.117.191932.","DOI":"10.2967\/jnumed.117.191932"},{"key":"6783_CR23","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1007\/s00259-009-1270-2","volume":"37","author":"F Nyuyki","year":"2010","unstructured":"Nyuyki F, Plotkin M, Graf R, Michel R, Steffen I, Denecke T, et al. Potential impact of (68)Ga-DOTATOC PET\/CT on stereotactic radiotherapy planning of meningiomas. Eur J Nucl Med Mol Imaging. 2010;37:310\u20138. https:\/\/doi.org\/10.1007\/s00259-009-1270-2.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6783_CR24","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/1748-717X-4-56","volume":"4","author":"B Gehler","year":"2009","unstructured":"Gehler B, Paulsen F, Oksuz MO, Hauser TK, Eschmann SM, Bares R, et al. [68Ga]-DOTATOC-PET\/CT for meningioma IMRT treatment planning. Radiat Oncol. 2009;4:56. https:\/\/doi.org\/10.1186\/1748-717X-4-56.","journal-title":"Radiat Oncol"},{"key":"6783_CR25","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.ijrobp.2012.03.021","volume":"85","author":"R Graf","year":"2013","unstructured":"Graf R, Nyuyki F, Steffen IG, Michel R, Fahdt D, Wust P, et al. Contribution of 68Ga-DOTATOC PET\/CT to target volume delineation of skull base meningiomas treated with stereotactic radiation therapy. Int J Radiat Oncol Biol Phys. 2013;85:68\u201373. https:\/\/doi.org\/10.1016\/j.ijrobp.2012.03.021.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"6783_CR26","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1186\/s13014-021-01875-6","volume":"16","author":"ES Kowalski","year":"2021","unstructured":"Kowalski ES, Khairnar R, Gryaznov AA, Kesari V, Koroulakis A, Raghavan P, et al. (68)Ga-DOTATATE PET-CT as a tool for radiation planning and evaluating treatment responses in the clinical management of meningiomas. Radiat Oncol. 2021;16:151. https:\/\/doi.org\/10.1186\/s13014-021-01875-6.","journal-title":"Radiat Oncol"},{"key":"6783_CR27","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1097\/RLU.0000000000004518","volume":"48","author":"CF Ghomari","year":"2023","unstructured":"Ghomari CF, Bender L, Lhermitte B, Noel G, Namer IJ, Bund C. 68Ga-DOTATOC PET in Extracranial Hepatic and Bone Metastasis of Atypical Refractory Meningioma: A Case Report. Clin Nucl Med. 2023;48:176\u20138. https:\/\/doi.org\/10.1097\/RLU.0000000000004518.","journal-title":"Clin Nucl Med"},{"key":"6783_CR28","doi-asserted-by":"publisher","first-page":"2216","DOI":"10.1158\/1078-0432.CCR-20-3362","volume":"27","author":"A Bashir","year":"2021","unstructured":"Bashir A, Larsen VA, Ziebell M, Fugleholm K, Law I. Improved Detection of Postoperative Residual Meningioma with [(68)Ga]Ga-DOTA-TOC PET Imaging Using a High-resolution Research Tomograph PET Scanner. Clin Cancer Res. 2021;27:2216\u201325. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-3362.","journal-title":"Clin Cancer Res"},{"key":"6783_CR29","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1093\/neuros\/nyaa333","volume":"88","author":"M Ueberschaer","year":"2020","unstructured":"Ueberschaer M, Vettermann FJ, Forbrig R, Unterrainer M, Siller S, Biczok AM, et al. Simpson Grade Revisited - Intraoperative Estimation of the Extent of Resection in Meningiomas Versus Postoperative Somatostatin Receptor Positron Emission Tomography\/Computed Tomography and Magnetic Resonance Imaging. Neurosurgery. 2020;88:140\u20136. https:\/\/doi.org\/10.1093\/neuros\/nyaa333.","journal-title":"Neurosurgery"},{"key":"6783_CR30","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1093\/neuonc\/now060","volume":"18","author":"K Seystahl","year":"2016","unstructured":"Seystahl K, Stoecklein V, Schuller U, Rushing E, Nicolas G, Schafer N, et al. Somatostatin receptor-targeted radionuclide therapy for progressive meningioma: benefit linked to 68Ga-DOTATATE\/-TOC uptake. Neuro Oncol. 2016;18:1538\u201347. https:\/\/doi.org\/10.1093\/neuonc\/now060.","journal-title":"Neuro Oncol"},{"key":"6783_CR31","doi-asserted-by":"publisher","first-page":"2577","DOI":"10.1007\/s00259-020-04759-1","volume":"47","author":"A Bashir","year":"2020","unstructured":"Bashir A, Vestergaard MB, Binderup T, Broholm H, Marner L, Ziebell M, et al. Pharmacokinetic analysis of [(68)Ga]Ga-DOTA-TOC PET in meningiomas for assessment of in vivo somatostatin receptor subtype 2. Eur J Nucl Med Mol Imaging. 2020;47:2577\u201388. https:\/\/doi.org\/10.1007\/s00259-020-04759-1.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"12","key":"6783_CR32","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1093\/neuonc\/nox112","volume":"19","author":"N Galldiks","year":"2017","unstructured":"Galldiks N, Albert NL, Sommerauer M, Grosu AL, Ganswindt U, Law I, et al. PET Imaging in patients with Meningioma - Report of the RANO\/PET Group. Neuro Oncol. 2017;19(12):1576\u201387. https:\/\/doi.org\/10.1093\/neuonc\/nox112.","journal-title":"Neuro Oncol"},{"key":"6783_CR33","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1093\/neuonc\/noab150","volume":"23","author":"R Goldbrunner","year":"2021","unstructured":"Goldbrunner R, Stavrinou P, Jenkinson MD, Sahm F, Mawrin C, Weber DC, et al. EANO guideline on the diagnosis and management of meningiomas. Neuro Oncol. 2021;23:1821\u201334. https:\/\/doi.org\/10.1093\/neuonc\/noab150.","journal-title":"Neuro Oncol"},{"key":"6783_CR34","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1007\/s00259-017-3728-y","volume":"44","author":"MF Bozkurt","year":"2017","unstructured":"Bozkurt MF, Virgolini I, Balogova S, Beheshti M, Rubello D, Decristoforo C, et al. Guideline for PET\/CT imaging of neuroendocrine neoplasms with (68)Ga-DOTA-conjugated somatostatin receptor targeting peptides and (18)F-DOPA. Eur J Nucl Med Mol Imaging. 2017;44:1588\u2013601. https:\/\/doi.org\/10.1007\/s00259-017-3728-y.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6783_CR35","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1007\/s00259-019-04501-6","volume":"47","author":"H Ilhan","year":"2020","unstructured":"Ilhan H, Lindner S, Todica A, Cyran CC, Tiling R, Auernhammer CJ, et al. Biodistribution and first clinical results of (18)F-SiFAlin-TATE PET: a novel (18)F-labeled somatostatin analog for imaging of neuroendocrine tumors. Eur J Nucl Med Mol Imaging. 2020;47:870\u201380. https:\/\/doi.org\/10.1007\/s00259-019-04501-6.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6783_CR36","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1097\/RLU.0000000000003607","volume":"46","author":"M Unterrainer","year":"2021","unstructured":"Unterrainer M, Lindner S, Beyer L, Gildehaus FJ, Todica A, Mittlmeier LM, et al. PET Imaging of Meningioma Using the Novel SSTR-Targeting Peptide 18F-SiTATE. Clin Nucl Med. 2021;46:667\u20138. https:\/\/doi.org\/10.1097\/RLU.0000000000003607.","journal-title":"Clin Nucl Med"},{"key":"6783_CR37","doi-asserted-by":"publisher","DOI":"10.3174\/ajnr.A7901","author":"J Rodriguez","year":"2023","unstructured":"Rodriguez J, Martinez G, Mahase S, Roytman M, Haghdel A, Kim S, et al. Cost-Effectiveness Analysis of (68)Ga-DOTATATE PET\/MRI in Radiotherapy Planning in Patients with Intermediate-Risk Meningioma. AJNR Am J Neuroradiol. 2023. https:\/\/doi.org\/10.3174\/ajnr.A7901.","journal-title":"AJNR Am J Neuroradiol"},{"key":"6783_CR38","doi-asserted-by":"publisher","first-page":"3353","DOI":"10.1007\/s00259-022-05738-4","volume":"49","author":"N Gillings","year":"2022","unstructured":"Gillings N, Hjelstuen O, Behe M, Decristoforo C, Elsinga PH, Ferrari V, et al. EANM guideline on quality risk management for radiopharmaceuticals. Eur J Nucl Med Mol Imaging. 2022;49:3353\u201364. https:\/\/doi.org\/10.1007\/s00259-022-05738-4.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6783_CR39","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1007\/s00259-022-05694-z","volume":"49","author":"H Hendrikse","year":"2022","unstructured":"Hendrikse H, Kiss O, Kunikowska J, Wadsak W, Decristoforo C, Patt M. EANM position on the in-house preparation of radiopharmaceuticals. Eur J Nucl Med Mol Imaging. 2022;49:1095\u20138. https:\/\/doi.org\/10.1007\/s00259-022-05694-z.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6783_CR40","doi-asserted-by":"crossref","first-page":"15N","DOI":"10.2967\/jnumed.115.162966","volume":"57","author":"ST Treves","year":"2016","unstructured":"Treves ST, Gelfand MJ, Fahey FH, Parisi MT. 2016 Update of the North American Consensus Guidelines for Pediatric Administered Radiopharmaceutical Activities. J Nucl Med. 2016;57:15N-N18.","journal-title":"J Nucl Med"},{"key":"6783_CR41","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1097\/RLU.0000000000002422","volume":"44","author":"M Unterrainer","year":"2019","unstructured":"Unterrainer M, Ilhan H, Vettermann F, Cyran CC, Tonn JC, Niyazi M, et al. Whole-Body Staging of Metastatic Atypical Meningioma Using 68Ga-DOTATATE PET\/CT. Clin Nucl Med. 2019;44:227\u20138. https:\/\/doi.org\/10.1097\/RLU.0000000000002422.","journal-title":"Clin Nucl Med"},{"key":"6783_CR42","doi-asserted-by":"publisher","first-page":"e210067","DOI":"10.1148\/rycan.210067","volume":"4","author":"J Ivanidze","year":"2022","unstructured":"Ivanidze J, Roytman M, Skafida M, Kim S, Glynn S, Osborne JR, et al. Dynamic (68)Ga-DOTATATE PET\/MRI in the Diagnosis and Management of Intracranial Meningiomas. Radiol Imaging Cancer. 2022;4:e210067. https:\/\/doi.org\/10.1148\/rycan.210067.","journal-title":"Radiol Imaging Cancer"},{"key":"6783_CR43","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.neuroimage.2013.08.042","volume":"84","author":"FL Andersen","year":"2014","unstructured":"Andersen FL, Ladefoged CN, Beyer T, Keller SH, Hansen AE, Hojgaard L, et al. Combined PET\/MR imaging in neurology: MR-based attenuation correction implies a strong spatial bias when ignoring bone. Neuroimage. 2014;84:206\u201316. https:\/\/doi.org\/10.1016\/j.neuroimage.2013.08.042.","journal-title":"Neuroimage"},{"key":"6783_CR44","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1007\/s11307-017-1123-5","volume":"20","author":"DL Bailey","year":"2018","unstructured":"Bailey DL, Pichler BJ, Guckel B, Antoch G, Barthel H, Bhujwalla ZM, et al. Combined PET\/MRI: Global Warming-Summary Report of the 6th International Workshop on PET\/MRI, March 27\u201329, 2017, Tubingen, Germany. Mol Imaging Biol. 2018;20:4\u201320. https:\/\/doi.org\/10.1007\/s11307-017-1123-5.","journal-title":"Mol Imaging Biol"},{"key":"6783_CR45","doi-asserted-by":"publisher","first-page":"918","DOI":"10.2967\/jnumed.115.166967","volume":"57","author":"T Koesters","year":"2016","unstructured":"Koesters T, Friedman KP, Fenchel M, Zhan Y, Hermosillo G, Babb J, et al. Dixon sequence with superimposed model-based bone compartment provides highly accurate PET\/MR attenuation correction of the brain. J Nucl Med. 2016;57:918\u201324. https:\/\/doi.org\/10.2967\/jnumed.115.166967.","journal-title":"J Nucl Med"},{"key":"6783_CR46","doi-asserted-by":"publisher","first-page":"453","DOI":"10.3389\/fnins.2017.00453","volume":"11","author":"CN Ladefoged","year":"2017","unstructured":"Ladefoged CN, Andersen FL, Kjaer A, Hojgaard L, Law I. RESOLUTE PET\/MRI Attenuation Correction for O-(2-(18)F-fluoroethyl)-L-tyrosine (FET) in Brain Tumor Patients with Metal Implants. Front Neurosci. 2017;11:453. https:\/\/doi.org\/10.3389\/fnins.2017.00453.","journal-title":"Front Neurosci"},{"key":"6783_CR47","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/j.neuroimage.2016.12.010","volume":"147","author":"CN Ladefoged","year":"2017","unstructured":"Ladefoged CN, Law I, Anazodo U, St Lawrence K, Izquierdo-Garcia D, Catana C, et al. A multi-centre evaluation of eleven clinically feasible brain PET\/MRI attenuation correction techniques using a large cohort of patients. Neuroimage. 2017;147:346\u201359. https:\/\/doi.org\/10.1016\/j.neuroimage.2016.12.010.","journal-title":"Neuroimage"},{"key":"6783_CR48","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.2967\/jnumed.116.186148","volume":"58","author":"I Rausch","year":"2017","unstructured":"Rausch I, Rischka L, Ladefoged CN, Furtner J, Fenchel M, Hahn A, et al. PET\/MRI for oncologic brain imaging: A comparison of standard mr-based attenuation corrections with a model-based approach for the siemens mMR PET\/MR system. J Nucl Med. 2017;58:1519\u201325. https:\/\/doi.org\/10.2967\/jnumed.116.186148.","journal-title":"J Nucl Med"},{"key":"6783_CR49","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s40658-014-0101-0","volume":"1","author":"CN Ladefoged","year":"2014","unstructured":"Ladefoged CN, Hansen AE, Keller SH, Holm S, Law I, Beyer T, et al. Impact of incorrect tissue classification in Dixon-based MR-AC: fat-water tissue inversion. EJNMMI Phys. 2014;1:101. https:\/\/doi.org\/10.1186\/s40658-014-0101-0.","journal-title":"EJNMMI Phys"},{"key":"6783_CR50","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s40658-015-0112-5","volume":"2","author":"CN Ladefoged","year":"2015","unstructured":"Ladefoged CN, Hansen AE, Keller SH, Fischer BM, Rasmussen JH, Law I, et al. Dental artifacts in the head and neck region: implications for Dixon-based attenuation correction in PET\/MR. EJNMMI Phys. 2015;2:8. https:\/\/doi.org\/10.1186\/s40658-015-0112-5.","journal-title":"EJNMMI Phys"},{"key":"6783_CR51","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1097\/RLI.0000000000000131","volume":"50","author":"C Brendle","year":"2015","unstructured":"Brendle C, Schmidt H, Oergel A, Bezrukov I, Mueller M, Schraml C, et al. Segmentation-based attenuation correction in positron emission tomography\/magnetic resonance: erroneous tissue identification and its impact on positron emission tomography interpretation. Invest Radiol. 2015;50:339\u201346. https:\/\/doi.org\/10.1097\/RLI.0000000000000131.","journal-title":"Invest Radiol"},{"key":"6783_CR52","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1007\/s00259-017-3619-2","volume":"44","author":"E Ter Voert","year":"2017","unstructured":"Ter Voert E, Veit-Haibach P, Ahn S, Wiesinger F, Khalighi MM, Levin CS, et al. Clinical evaluation of TOF versus non-TOF on PET artifacts in simultaneous PET\/MR: a dual centre experience. Eur J Nucl Med Mol Imaging. 2017;44:1223\u201333. https:\/\/doi.org\/10.1007\/s00259-017-3619-2.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6783_CR53","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.2967\/jnumed.118.220871","volume":"60","author":"A Rezaei","year":"2019","unstructured":"Rezaei A, Schramm G, Willekens SMA, Delso G, Van Laere K, Nuyts J. A Quantitative Evaluation of Joint Activity and Attenuation Reconstruction in TOF PET\/MR Brain Imaging. J Nucl Med. 2019;60:1649\u201355. https:\/\/doi.org\/10.2967\/jnumed.118.220871.","journal-title":"J Nucl Med"},{"key":"6783_CR54","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s40658-016-0169-9","volume":"4","author":"OL Munk","year":"2017","unstructured":"Munk OL, Tolbod LP, Hansen SB, Bogsrud TV. Point-spread function reconstructed PET images of sub-centimeter lesions are not quantitative. EJNMMI Phys. 2017;4:5. https:\/\/doi.org\/10.1186\/s40658-016-0169-9.","journal-title":"EJNMMI Phys"},{"key":"6783_CR55","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s00259-017-3740-2","volume":"44","author":"N Aide","year":"2017","unstructured":"Aide N, Lasnon C, Veit-Haibach P, Sera T, Sattler B, Boellaard R. EANM\/EARL harmonization strategies in PET quantification: from daily practice to multicentre oncological studies. Eur J Nucl Med Mol Imaging. 2017;44:17\u201331. https:\/\/doi.org\/10.1007\/s00259-017-3740-2.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6783_CR56","first-page":"322","volume":"34","author":"S Minoshima","year":"1993","unstructured":"Minoshima S, Koeppe RA, Mintun MA, Berger KL, Taylor SF, Frey KA, et al. Automated detection of the intercommissural line for stereotactic localization of functional brain images. J Nucl Med. 1993;34:322\u20139.","journal-title":"J Nucl Med"},{"key":"6783_CR57","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1111\/jon.12632","volume":"29","author":"J Ivanidze","year":"2019","unstructured":"Ivanidze J, Roytman M, Lin E, Magge RS, Pisapia DJ, Liechty B, et al. Gallium-68 DOTATATE PET in the Evaluation of Intracranial Meningiomas. J Neuroimaging. 2019;29:650\u20136. https:\/\/doi.org\/10.1111\/jon.12632.","journal-title":"J Neuroimaging"},{"key":"6783_CR58","doi-asserted-by":"publisher","first-page":"9256","DOI":"10.1038\/s41598-022-13467-9","volume":"12","author":"SH Kim","year":"2022","unstructured":"Kim SH, Roytman M, Madera G, Magge RS, Liechty B, Ramakrishna R, et al. Evaluating diagnostic accuracy and determining optimal diagnostic thresholds of different approaches to [(68)Ga]-DOTATATE PET\/MRI analysis in patients with meningioma. Sci Rep. 2022;12:9256. https:\/\/doi.org\/10.1038\/s41598-022-13467-9.","journal-title":"Sci Rep"},{"key":"6783_CR59","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-023-09697-8","author":"C Boursier","year":"2023","unstructured":"Boursier C, Zaragori T, Bros M, Bordonne M, Melki S, Taillandier L, et al. Semi-automated segmentation methods of SSTR PET for dosimetry prediction in refractory meningioma patients treated by SSTR-targeted peptide receptor radionuclide therapy. Eur Radiol. 2023. https:\/\/doi.org\/10.1007\/s00330-023-09697-8.","journal-title":"Eur Radiol"},{"key":"6783_CR60","doi-asserted-by":"publisher","first-page":"171","DOI":"10.2967\/jnumed.114.147256","volume":"56","author":"N Marincek","year":"2015","unstructured":"Marincek N, Radojewski P, Dumont RA, Brunner P, Muller-Brand J, Maecke HR, et al. Somatostatin receptor-targeted radiopeptide therapy with 90Y-DOTATOC and 177Lu-DOTATOC in progressive meningioma: long-term results of a phase II clinical trial. J Nucl Med. 2015;56:171\u20136. https:\/\/doi.org\/10.2967\/jnumed.114.147256.","journal-title":"J Nucl Med"},{"key":"6783_CR61","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.2967\/jnumed.115.155853","volume":"56","author":"K Gerster-Gillieron","year":"2015","unstructured":"Gerster-Gillieron K, Forrer F, Maecke H, Mueller-Brand J, Merlo A, Cordier D. 90Y-DOTATOC as a Therapeutic Option for Complex Recurrent or Progressive Meningiomas. J Nucl Med. 2015;56:1748\u201351. https:\/\/doi.org\/10.2967\/jnumed.115.155853.","journal-title":"J Nucl Med"},{"key":"6783_CR62","doi-asserted-by":"publisher","unstructured":"Kriwanek F, Ulbrich L, Lechner W, Lutgendorf-Caucig C, Konrad S, Waldstein C, et al. Impact of SSTR PET on Inter-Observer Variability of Target Delineation of Meningioma and the Possibility of Using Threshold-Based Segmentations in Radiation Oncology. Cancers (Basel). 2022;14. https:\/\/doi.org\/10.3390\/cancers14184435.","DOI":"10.3390\/cancers14184435"},{"key":"6783_CR63","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.clinimag.2020.04.026","volume":"66","author":"M Roytman","year":"2020","unstructured":"Roytman M, Pisapia DJ, Liechty B, Lin E, Skafida M, Magge RS, et al. Somatostatin receptor-2 negative meningioma: pathologic correlation and imaging implications. Clin Imaging. 2020;66:18\u201322. https:\/\/doi.org\/10.1016\/j.clinimag.2020.04.026.","journal-title":"Clin Imaging"},{"key":"6783_CR64","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1097\/RLU.0000000000001793","volume":"42","author":"M Unterrainer","year":"2017","unstructured":"Unterrainer M, Ilhan H, Todica A, Bartenstein P, Albert NL. Epidural Metastases From Follicular Thyroid Cancer Mimicking Meningiomas in 68Ga-DOTATATE PET. Clin Nucl Med. 2017;42:805\u20136. https:\/\/doi.org\/10.1097\/RLU.0000000000001793.","journal-title":"Clin Nucl Med"},{"key":"6783_CR65","doi-asserted-by":"publisher","first-page":"e279","DOI":"10.1097\/RLU.0000000000003012","volume":"45","author":"A Bashir","year":"2020","unstructured":"Bashir A, Broholm H, Clasen-Linde E, Vestergaard MB, Law I. Pearls and Pitfalls in Interpretation of 68Ga-DOTATOC PET Imaging. Clin Nucl Med. 2020;45:e279\u201380. https:\/\/doi.org\/10.1097\/RLU.0000000000003012.","journal-title":"Clin Nucl Med"},{"key":"6783_CR66","doi-asserted-by":"publisher","first-page":"e2512","DOI":"10.1212\/WNL.0000000000007544","volume":"92","author":"M Unterrainer","year":"2019","unstructured":"Unterrainer M, Ruf V, Ilhan H, Vettermann F, Holzgreve A, Cyran CC, et al. Teaching NeuroImages: Advanced imaging of neurosarcoidosis with (68)Ga-DOTATATE PET\/CT. Neurology. 2019;92:e2512\u20133. https:\/\/doi.org\/10.1212\/WNL.0000000000007544.","journal-title":"Neurology"},{"key":"6783_CR67","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1093\/neuonc\/noy137","volume":"21","author":"RY Huang","year":"2019","unstructured":"Huang RY, Bi WL, Weller M, Kaley T, Blakeley J, Dunn I, et al. Proposed response assessment and endpoints for meningioma clinical trials: report from the Response Assessment in Neuro-Oncology Working Group. Neuro Oncol. 2019;21:26\u201336. https:\/\/doi.org\/10.1093\/neuonc\/noy137.","journal-title":"Neuro Oncol"},{"key":"6783_CR68","doi-asserted-by":"publisher","first-page":"i44","DOI":"10.1093\/neuonc\/noy143","volume":"21","author":"RY Huang","year":"2019","unstructured":"Huang RY, Bi WL, Griffith B, Kaufmann TJ, la Fougere C, Schmidt NO, et al. Imaging and diagnostic advances for intracranial meningiomas. Neuro Oncol. 2019;21:i44\u201361. https:\/\/doi.org\/10.1093\/neuonc\/noy143.","journal-title":"Neuro Oncol"},{"key":"6783_CR69","doi-asserted-by":"publisher","first-page":"e29","DOI":"10.1016\/S1470-2045(23)00525-9","volume":"25","author":"NL Albert","year":"2024","unstructured":"Albert NL, Galldiks N, Ellingson BM, van den Bent MJ, Chang SM, Cicone F, et al. PET-based response assessment criteria for diffuse gliomas (PET RANO 1.0): a report of the RANO group. Lancet Oncol. 2024;25:e29\u201341. https:\/\/doi.org\/10.1016\/S1470-2045(23)00525-9.","journal-title":"Lancet Oncol."},{"key":"6783_CR70","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1158\/1078-0432.CCR-23-2533","volume":"30","author":"SC Kurz","year":"2024","unstructured":"Kurz SC, Zan E, Cordova C, Troxel AB, Barbaro M, Silverman JS, et al. Evaluation of the SSTR2-targeted Radiopharmaceutical 177Lu-DOTATATE and SSTR2-specific 68Ga-DOTATATE PET as Imaging Biomarker in Patients with Intracranial Meningioma. Clin Cancer Res. 2024;30:680\u20136. https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-2533.","journal-title":"Clin Cancer Res"},{"key":"6783_CR71","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s11102-023-01329-0","volume":"26","author":"SH Kim","year":"2023","unstructured":"Kim SH, Chang SJC, Dobri G, Strauss S, Lin E, Zavaletta V, et al. [68 Ga]-DOTATATE PET\/MR-based evaluation of physiologic somatostatin receptor 2 expression in the adult pituitary gland as a function of age and sex in a prospective cohort. Pituitary. 2023;26:419\u201328. https:\/\/doi.org\/10.1007\/s11102-023-01329-0.","journal-title":"Pituitary"},{"key":"6783_CR72","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s13550-015-0106-2","volume":"5","author":"A Kiviniemi","year":"2015","unstructured":"Kiviniemi A, Gardberg M, Frantzen J, Pesola M, Vuorinen V, Parkkola R, et al. Somatostatin receptor subtype 2 in high-grade gliomas: PET\/CT with (68)Ga-DOTA-peptides, correlation to prognostic markers, and implications for targeted radiotherapy. EJNMMI Res. 2015;5:25. https:\/\/doi.org\/10.1186\/s13550-015-0106-2.","journal-title":"EJNMMI Res"},{"key":"6783_CR73","doi-asserted-by":"publisher","first-page":"E278","DOI":"10.1152\/ajpendo.00004.2005","volume":"289","author":"J van der Hoek","year":"2005","unstructured":"van der Hoek J, Waaijers M, van Koetsveld PM, Sprij-Mooij D, Feelders RA, Schmid HA, et al. Distinct functional properties of native somatostatin receptor subtype 5 compared with subtype 2 in the regulation of ACTH release by corticotroph tumor cells. Am J Physiol Endocrinol Metab. 2005;289:E278\u201387. https:\/\/doi.org\/10.1152\/ajpendo.00004.2005.","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"6783_CR74","doi-asserted-by":"publisher","first-page":"406","DOI":"10.2967\/jnumed.121.262491","volume":"63","author":"EPA Vonken","year":"2022","unstructured":"Vonken EPA, Bruijnen RCG, Snijders TJ, Seute T, Lam M, Keizer B, et al. Intraarterial Administration Boosts (177)Lu-HA-DOTATATE Accumulation in Salvage Meningioma Patients. J Nucl Med. 2022;63:406\u20139. https:\/\/doi.org\/10.2967\/jnumed.121.262491.","journal-title":"J Nucl Med"},{"key":"6783_CR75","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/1748-717X-7-99","volume":"7","author":"MC Kreissl","year":"2012","unstructured":"Kreissl MC, Hanscheid H, Lohr M, Verburg FA, Schiller M, Lassmann M, et al. Combination of peptide receptor radionuclide therapy with fractionated external beam radiotherapy for treatment of advanced symptomatic meningioma. Radiat Oncol. 2012;7:99. https:\/\/doi.org\/10.1186\/1748-717X-7-99.","journal-title":"Radiat Oncol"},{"key":"6783_CR76","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.ctro.2020.03.002","volume":"22","author":"PE Hartrampf","year":"2020","unstructured":"Hartrampf PE, Hanscheid H, Kertels O, Schirbel A, Kreissl MC, Flentje M, et al. Long-term results of multimodal peptide receptor radionuclide therapy and fractionated external beam radiotherapy for treatment of advanced symptomatic meningioma. Clin Transl Radiat Oncol. 2020;22:29\u201332. https:\/\/doi.org\/10.1016\/j.ctro.2020.03.002.","journal-title":"Clin Transl Radiat Oncol"},{"key":"6783_CR77","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1007\/s00259-022-05727-7","volume":"49","author":"K Sjogreen Gleisner","year":"2022","unstructured":"Sjogreen Gleisner K, Chouin N, Gabina PM, Cicone F, Gnesin S, Stokke C, et al. EANM dosimetry committee recommendations for dosimetry of 177Lu-labelled somatostatin-receptor- and PSMA-targeting ligands. Eur J Nucl Med Mol Imaging. 2022;49:1778\u2013809. https:\/\/doi.org\/10.1007\/s00259-022-05727-7.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6783_CR78","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1007\/s00259-017-3675-7","volume":"44","author":"J van der Pol","year":"2017","unstructured":"van der Pol J, Voo S, Bucerius J, Mottaghy FM. Consequences of radiopharmaceutical extravasation and therapeutic interventions: a systematic review. Eur J Nucl Med Mol Imaging. 2017;44:1234\u201343. https:\/\/doi.org\/10.1007\/s00259-017-3675-7.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6783_CR79","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1007\/s00259-007-0372-y","volume":"34","author":"J Tennvall","year":"2007","unstructured":"Tennvall J, Fischer M, Bischof Delaloye A, Bombardieri E, Bodei L, Giammarile F, et al. EANM procedure guideline for radio-immunotherapy for B-cell lymphoma with 90Y-radiolabelled ibritumomab tiuxetan (Zevalin). Eur J Nucl Med Mol Imaging. 2007;34:616\u201322. https:\/\/doi.org\/10.1007\/s00259-007-0372-y.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6783_CR80","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1016\/S1470-2045(21)00572-6","volume":"22","author":"JR Strosberg","year":"2021","unstructured":"Strosberg JR, Caplin ME, Kunz PL, Ruszniewski PB, Bodei L, Hendifar A, et al. (177)Lu-Dotatate plus long-acting octreotide versus high-dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial. Lancet Oncol. 2021;22:1752\u201363. https:\/\/doi.org\/10.1016\/S1470-2045(21)00572-6.","journal-title":"Lancet Oncol"},{"key":"6783_CR81","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1007\/s00259-014-2961-x","volume":"42","author":"R Boellaard","year":"2015","unstructured":"Boellaard R, Delgado-Bolton R, Oyen WJ, Giammarile F, Tatsch K, Eschner W, et al. FDG PET\/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2015;42:328\u201354. https:\/\/doi.org\/10.1007\/s00259-014-2961-x.","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"6783_CR82","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s00259-009-1297-4","volume":"37","author":"R Boellaard","year":"2010","unstructured":"Boellaard R, O\u2019Doherty MJ, Weber WA, Mottaghy FM, Lonsdale MN, Stroobants SG, et al. FDG PET and PET\/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. Eur J Nucl Med Mol Imaging. 2010;37:181\u2013200. https:\/\/doi.org\/10.1007\/s00259-009-1297-4.","journal-title":"Eur J Nucl Med Mol Imaging."}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-024-06783-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-024-06783-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-024-06783-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T01:28:56Z","timestamp":1727746136000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-024-06783-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,20]]},"references-count":82,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["6783"],"URL":"https:\/\/doi.org\/10.1007\/s00259-024-06783-x","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,20]]},"assertion":[{"value":"4 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"NLA has received honoraria for lectures,\u00a0consultation or advisory board participation from Novartis, Advanced Accelerator Applications, Servier, OncLive and Telix Pharmaceuticals and research funding from Novocure.MP has received honoraria for lectures, consultation or advisory board participation from the following for-profit companies: Bayer, Bristol-Myers Squibb, Novartis, Gerson Lehrman Group (GLG), CMC Contrast, GlaxoSmithKline, Mundipharma, Roche, BMJ Journals, MedMedia, Astra Zeneca, AbbVie, Lilly, Medahead, Daiichi Sankyo, Sanofi, Merck Sharp & Dome, Tocagen, Adastra, Gan & Lee Pharmaceuticals, Servier,\u00a0Miltenyi, B\u00f6hringer-Ingelheim, Telix, Medscape, OncLive.AV has received honoraria for lectures and advisory board participation from Curium, Eisai and General Electrics.CMD is\/has been a consultant for: Sirtex, Advanced Accelerator Applications, Novartis, Ipsen, Terumo, PSI CRO. He has received travel fees from: GE Healthcare, Sirtex.KH reports personal fees from Bayer, personal fees and other from Sofie Biosciences, personal fees from SIRTEX, non-financial support from ABX, personal fees from Adacap, personal fees from Curium, personal fees from Endocyte, grants and personal fees from BTG, personal fees from IPSEN, personal fees from Siemens Healthineers, personal fees from GE Healthcare, personal fees from Amgen, personal fees from Fusion, personal fees from Immedica, personal fees from Onkowissen.de, personal fees from Novartis, personal fees from Molecular Partners, personal fees from ymabs, personal fees from Aktis Oncology, personal fees from Theragnostics, personal fees from Pharma15, personal fees from Debiopharm, personal fees from AstraZeneca, personal fees from Janssen.JCT has received research grants and honoraria for lectures, consultation or advisory board participation from the following for-profit companies: AAA-Novartis, Seagen, CarThera, Munich Surgical Imaging, Novocure.PYW has received research support from Astra Zeneca, Black Diamond, Bristol Meyers Squibb, Celgene, Chimerix, Eli Lily, Erasca, Genentech\/Roche, Kazia, MediciNova, Merck, Novartis, Nuvation Bio, Servier, Vascular Biogenics, VBI Vaccines and honoraria for consultation or advisiory board participation from Astra Zeneca, Black Diamond, Celularity, Chimerix, Day One Bio, Genenta, Glaxo Smith Kline, Merck, Mundipharma, Novartis, Novocure, Nuvation Bio, Prelude Therapeutics, Sapience, Servier, Sagimet, Vascular Biogenics, VBI Vaccines.JF has received honoraria for lectures and consultations from the following for-profit companies: Novartis, Seagen, Sanova, Servier.JI has received research support from Novartis Pharmaceuticals (funds paid to institution, investigator-initiated trial grant).RYH has received honoraria for consultation from Nuvation Bio, Servier and Telix, and honoraria for participiation in Scientific Advisory Boards from Vysioneer.DRJ has received honoraria for consultation or advisory board participation from Novartis and Telix Pharmaceuticals.EG has received honoraria for consultation or advisory board participation from Novartis.JDP reports grants from the NIH and Genentech; Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Varian Medical Systems, Novocure, ICOTEC; Travel support from Varian, ICOTEC; Participation on a Data Safety Monitoring Board or Advisory Board from Novocure.MVDB has received honoraria for consultancy from Chimerix, Servier, Astra Zeneca, Boehringer-Ingelheim, Nerviano, Incyte, Biopharma, and Genenta.NG has received honoraria for lectures from Blue Earth Diagnostics, and for advisory board participation from Telix Pharmaceuticals.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}